Professor Philip Strange has worked on the structure and function of G protein-coupled receptors for many years. A major focus of his work has been the receptors for the neurotransmitter dopamine, with particular emphasis on their role as targets for drugs and understanding the mechanisms of agonism and inverse agonism at these receptors.
Professor Kim Neve has studied dopamine receptors for most of his scientific career, with an emphasis on relating structural features of the receptors to specific functions and assessing how receptor responsiveness is altered by denervation or prolonged treatment with agonists.
History
It was not until the late 1950s that dopamine was recognized as a neurotransmitter in its own right, but the demonstration of its non-uniform distribution in the brain, distinct from the distribution of noradrenaline, suggested a specific functional role for dopamine.
1 Interest in dopamine was intensified by the realization that dopamine had an important role in the pathogenesis or drug treatment of certain neurological disorders, e.g. Parkinson's disease and schizophrenia. 2, 3 This led to much research on the sites of action of dopamine and the dopamine receptors (Box 1). One milestone was the suggestion by Cools and van Rossum, based on anatomical, electrophysiological and pharmacological studies, that there might be more than one kind of receptor for dopamine in the brain. 4 Biochemical studies on dopamine receptors in the 1970s based on second messenger assays (e.g. stimulation of cAMP production and ligand binding assays) supported the idea, and it was given a firm foundation by Kebabian and Calne in their 1979 review. 5 They extended an earlier suggestion by Spano et al, 6 and proposed that there were two classes of dopamine receptor, D 1 and D 2 , with different biochemical and pharmacological properties, mediating different physiological functions. The properties of these two subtypes are summarized in Table 1 . Selective agonists and antagonists exist to define the two subtypes in functional assays and some of these are shown in Table 1 Table 1 ).
Although there were some indications of further heterogeneity of these dopamine receptor subtypes in biochemical studies, it was not until the late 1980s that the true extent of this was revealed with the application of gene cloning techniques. These studies have shown that there are at least five dopamine receptors (D 1 -D 5 ) that may be divided into two subfamilies whose properties resemble the original D 1 and D 2 receptors. Tables 2 and 3 .
In subsequent discussion we refer to receptor subtypes defined from cloned genes as D 1 , D 2 
Properties of the Dopamine Receptor Subtypes
Common receptor properties Analysis of the amino acid sequences of the dopamine receptor subtypes has shown that significant homologies exist among the subtypes, with the greatest being found between members of either subfamily. 7, 8 Each receptor has been shown to contain seven stretches of amino acids that are hydrophobic and long enough to span the membrane. It seems therefore that each of the dopamine receptors conforms to the general structural model for a GPCR, [9] [10] [11] with an extracellular amino terminus and seven putative membrane spanning α-helices linked by intracellular and extracellular protein loops (Figure 2) . One or more potential sites for glycosylation are found on the amino terminus and second extracellular loop. The helices are bundled together in the membrane to form the ligand binding site ( Figure 2) ; some information is available on the residues that make contact with ligands. 11, 12 There is an intracellular carboxyl terminus, probably bearing a palmitoyl group, which may form a further link to the membrane. The D 1 -like receptors have short third intracellular loops and long carboxyl terminal tails, whereas the D 2 -like receptors have long third intracellular loops and short carboxyl terminal tails. This provides a structural basis for the division of the receptors into two subfamilies but is also likely to have a functional significance, possibly related to the specificity of receptor/G protein interaction. The diagram shows the seven helices bundled together in the membrane and the intra-(I1, I2, I3) and extracellular (E1, E2, E3) loops. The ligand binding site is contained in the cavity formed between the helices. There may be an eighth helix formed in the carboxyl terminus parallel to the membrane (not shown). There is also a disulfide bond between E2 and the top of helix 3. The helices have been drawn parallel to one another for clarity but in fact there are kinks in the helices and they are not fully parallel. I3 and the carboxyl terminus contain multiple sites for phosphorylation that are involved in regulation of receptor responsiveness and interactions with adapter proteins. have differential abilities to couple to or activate G proteins, 18, 19 and may also exhibit slightly different pharmacological properties. 16, 20, 21 Lines of mice have been developed in which the I3 insertion that produces the long D 2 receptor variant (D 2L ) is deleted, resulting in the expression of only the short variant (D 2S ). Characterization of these mice suggests that the splice variants are not fully interchangeable; some D 2 receptor responses are not observed in mice that express only D 2S . [22] [23] [24] The variants of the D 4 receptor have not been found to exhibit any substantive differences in agonist signaling or in coupling to G proteins. 25 The individual properties of the different subtypes were initially probed by expressing the receptors in recombinant cells and examining the localization of the subtypes at the mRNA and protein level. More recently, the use of subtype-selective drugs and transgenic mice with one or more receptor subtypes genetically deleted has enabled further study of these receptors.
Individual receptor properties
The dopamine receptor subtypes exhibit different properties in terms of their pharmacological profile, localization, and mechanism of action; these differences will be briefly summarized below.
D 1 -like receptors
Both the D 1 and D 5 receptors show pharmacological properties similar to those of the original pharmacologically defined D 1 receptor, that is, a high affinity for the benzazepine ligands SCH 23390, SCH 39166, and SKF 83566, which are selective antagonists for these subtypes. Although not as selective for D 1 over D 2 as the benzazepine antagonists, LE 300 is a potent D 1 -like antagonist that is useful because it is structurally distinct from the benzazepines. Thioxanthines such as flupentixol and phenothiazines such as fluphenazine also show high affinity but are not selective for D 1 -like over D 2 -like receptors. The development of the first D 1 -like receptor agonist, SKF 38393, was important for differentiating between activation of D 1 -like and D 2 -like receptors, although it was later realized that the partial agonist nature of SKF 38393 produced an under-appreciation of the contribution of D 1 -like receptors to behavior. 26 The D 1 -like receptors show moderate affinities for typical dopamine agonists such as apomorphine; full and/or selective D 1 -like receptor agonists such as A 77636, A 68930, SKF 81297, dihydrexidine, and doxanthrine are now available (Box 2). There are minor differences in the affinities of some compounds for the D 1 and D 5 receptors (higher agonist and lower antagonist affinities for D 5 ), but no compounds that effectively distinguish between those subtypes are as yet available. 27, 28 D 1 receptors are found at high levels in the typical dopaminerich regions of brain such as the neostriatum, substantia nigra, nucleus accumbens, and olfactory tubercle, whereas the distribution of the D 5 receptors is much more restricted (Table 2) ; this subtype is found generally at much lower levels. Both receptors are able to stimulate adenylyl cyclase (Figure 1) , with the D 5 receptor showing some constitutive activity for this response. 28 Inverse agonist activity at the D 1 and D 5 receptors is seen in recombinant systems for some compounds such as butaclamol, 28 which were previously considered to be antagonists. It has been known for some time that stimulation of a D 1 -like receptor leads to activation of phospholipase C 29 and recently this response has been linked to the D 1 /D 2 receptor heterodimer, providing a function for heterodimer formation. 30 (Bold text denotes compounds available from Tocris at time of publication) The localization data are from functional and ligand-binding studies on dispersed tissues and tissue slices. 35, 36 Selective agonists for the D 2 -like receptors relative to the D 1 -like receptors, e.g. N-0437, PHNO, and quinpirole, have been developed. Sumanirole is a full-efficacy agonist that is highly selective for the D 2 receptor over other dopamine receptors. 37 There are a number of D 4 agonists of varying efficacy and selectivity, with A 412997 being an example of a highly selective full D 4 agonist (Box 5). 38 Many agonists appear to be highly selective for the D 3 receptor over other D 2 -like receptors in radioligand binding assays, but this frequently reflects an invalid comparison between a mixed population of agonist high-and low-affinity D 2 receptors, and the D 3 receptor that is apparently constrained in an agonist-high affinity conformation, 39 rather than a difference in drug concentrations capable of activating the two subtypes. 40 When care is taken to compare functional responses or binding to the agonist high-affinity state of the receptors, dopamine and some agonists such as pramipexole are determined to be modestly D 3 selective. 41 tocris.com |
Dopamine Receptors
The D 2 receptor is the predominant D 2 -like subtype in the brain, located at high levels in typical dopamine rich brain areas. D 3 and D 4 receptors are found at much lower levels and in a more restricted distribution pattern, located predominantly in limbic areas of the brain (Table 2 ). Some D 3 receptors are also found in regions associated with motor function such as the putamen. The D 2 -like receptor subtypes have each been shown to inhibit adenylyl cyclase (Figure 1 ) when expressed in recombinant cells, 40, 42, 43 although the signal via the D 3 receptor has proven more difficult to demonstrate and is generally lower than for the other two subtypes. This may relate to preferential coupling of the D 3 receptor to specific adenylyl cyclase isoforms. 44 The D 2 -like receptors will, upon activation, stimulate a range of processes including acute signaling events (inhibition of adenylyl cyclase, stimulation of K + channels, inhibition of Ca 2+ channels, stimulation of arachidonic acid release) and longer term events (MAP kinase and b-arrestin-2/Akt/GSK-3 sig naling, and mitogenesis). 45 ,46 D 3 receptor-mediated signaling events are often of lower magnitude than for the other D 2 -like receptors. The relation of these signaling events to in vivo responses is only beginning to be clarified. Many compounds that were thought to be antagonists at D 2 -like receptors -such as the antipsychotic drugs haloperidol, chlorpromazine, and clozapine -have been shown to possess inverse agonist activity at D 2 and D 3 receptors. [47] [48] [49] This inverse agonism may contribute to the increases in D 2 receptor number seen in the brain when experimental animals are treated chronically with these drugs.
The properties of the principal dopamine receptor subtypes identified by gene cloning are shown. They are divided into 'D 1 -like' and 'D 2 -like' groups to reflect amino acid homology, functional similarity, structural similarity, and pharmacological properties. This grouping conforms with a previous classification based on pharmacological and biochemical properties (Table 1) . D 2S and D 2L refer to different alternatively spliced forms of the D 2 receptor gene. The homology values are for the transmembrane-spanning regions. 69 The localizations and relative expression levels shown are the principal ones known at present from in-situ hybridization and use of the polymerase chain reaction. Some pharmacological data for the different receptor subtypes is given in Table 3 . *The human D 4 receptor has many longer allelic variants. For further information on the properties of the dopamine receptor subtypes, please consult reference 8.
Values for the dissociation constants are given for ligands, determined using ligand binding assays for the five dopamine receptor subtypes. As far as possible, values are given that avoid artefacts present in ligand binding assays with high affinity radioligands.3 †Data for dopamine were obtained in the presence of Gpp(NH)p and therefore represent the agonist low-affinity state. Data taken from references 3, 8, 21, 27 and 70. 
Future Directions
Understanding the role of the dopamine receptor subtypes
We are still a long way away from understanding the role of the different receptor subtypes. Although partially selective antagonists and transgenic 'receptor knock out' animals are available for some of the subtypes, much is still to be done here (see for example Waddington et al (2005) 31 ).
Dopamine receptor subtypes in drug discovery
Due to the importance of dopamine for the pathogenesis or drug treatment of several important disorders e.g. Parkinson's disease, schizophrenia and pituitary prolactin dysfunction, dopamine receptors have been very popular as targets for drug discovery campaigns (Box 6). This continues to be the case and indications have expanded into areas such as drug dependence and penile erectile dysfunction. A new development in the search for effective antipsychotics has been the development of dopamine D 2 -like partial agonists such as aripiprazole. 51 It had been thought that antipsychotics had to be antagonists/ inverse agonists at the D 2 receptor, 3 yet the effective use of D 2 partial agonists as antipsychotics raises questions about the mechanism of D 2 receptor-mediated antipsychotic activity that need to be addressed. 52 It will be important, for example, to understand the relationship between the efficacy of the ligands in signaling assays and their therapeutic effects.
An important new tool for the rational design of subtype-selective drugs is the availability of crystal structures for the D 3 receptor and the b 2 -adrenoceptor. 10, 11 These structures and the precise models that can be constructed on the basis of their close homology with other D 2 -like receptors and the D 1 -like receptor, respectively, make it possible to predict the affinity of a receptor for molecules that may be novel scaffolds. 53, 54 Biochemical mechanisms underlying the effects of dopamine receptor activation It will be very important to define clearly how activation of dopamine receptors leads to changes in the function of cells such as neurons. In time, this will lead to a better understanding of how drugs act on the brain. Important progress has been made in this area. For example, in striatal neurons it has been shown that a protein strongly regulated by dopamine receptors is DARPP-32 (dopamine and cAMP-regulated phosphoprotein 32 kD). DARPP-32 seems to be a key protein in striatal neuronal function. 55 Important progress has also been made in understanding temporal aspects of signaling processes in the brain. It has been suggested that there may be two waves of dopamine-mediated responses: one set of faster responses associated with changes in cAMP and DARPP-32 phosphorylation, and another slower set of non-cAMP mediated processes associated with b-arrestin-2/ Akt/GSK-3 signaling. 46 Interactions of dopamine receptors with other proteins It is becoming clear that interactions of the dopamine receptors with other proteins are very important in determining their function; this will be an active field of research in the future. As a group, the cytoskeletal, adapter, and signaling proteins that interact with dopamine receptors have been termed DRIPs (dopamine receptor-interacting proteins). 56 58 and roles for homodimer formation, e.g. D 2 homodimers, 59, 60 are being actively pursued.
Development and characterization of biased ligands
A promising new avenue for drug development is based on the observation that many ligands do not engage, to the same extent, all of the mechanisms that are consequences of activation of a receptor; activation of a receptor by its endogenous agonist may activate G protein-and b-arrestin-mediated signaling, phosphorylation of the receptor by one or more protein kinases, desensitization, and receptor internalization followed by either recycling or degradation of the receptor. A given ligand may be fully efficacious (i.e., a full agonist) for some of these responses, and a partial agonist or an antagonist at other responses mediated by the same receptor. 61, 62 This phenomenon is referred to as functional selectivity, and a ligand that engages only some of the repertoire of responses available to a receptor is a functionally selective (or 'biased') ligand.
The D 1 receptor is a promising target for treatment of Parkinson's disease, with two impediments to the use of D 1 agonists being rapid development of tolerance and the side effects of hypotension and seizures. 63 Both of these impediments could potentially be addressed through the development of biased agonists. For example, SKF 83822 is a functionally selective ligand biased towards D 1 -mediated signaling via adenylyl cyclase that also induces seizures at high doses, 64 while SKF 83959 preferentially activates the D 1 /D 2 receptor heteromer and the associated phospholipase C response. 30 Ligands biased towards either G protein-or b-arrestin-mediated signaling pathways modulated by the D 2 receptor are also of considerable interest as pharmacological tools and as potential antipsychotic drugs that may be more efficacious or have fewer side effects. tocris.com | 
